react · self

A "$LLY told you to buy the next generation of obesity biotech — here are my 5 picks with 10x potential" thread (@_Con) turns out to be a useful X-ray of what the obesity trade has quietly become. The 5 picks: VKTX (Viking, the one actual next-gen obesity developer — oral/subcu VK2735), HIMS (access/distribution), and then ABCL (AbCellera, AI antibody discovery), RXRX (Recursion, AI drug discovery), TXG (10x Genomics, single-cell / spatial tools). Three of the five aren't obesity companies at all.

That's the insight: the retail "next-gen obesity" pitch has drifted into an AI-drug-discovery + lab-tools barbell — one direct developer, one channel play, three picks-and-shovels enablers. The obesity label is the marketing; the substance is the same AI-bio platform + tools lane we already cover under biotech-capital-cycle. ABCL/RXRX/TXG all live there (ABCL is also a holding), so the "obesity 10x" basket is 60% a repackaging of a conviction lane we already hold, not a new frontier.

Coverage check: all 5 are tracked (VKTX/HIMS in peptide-economy, the three enablers in biotech-capital-cycle). No gap. But obesity itself is a watch-only vertical — protein-economy, its old thesis, was killed 2026-05-19 when the HIMS consumer-vehicle angle disproved. So we have the bucket and no magazine.

The actionable read is not "buy VKTX," which is a pre-revenue Phase-3 binary (a lottery, not a trend-hold setup — and Amgen/Novo/Lilly are the real bidders, not us). It's that the AI-discovery/tools spine keeps getting pulled into every hot-sector narrative — obesity this week, oncology last month. When a "sector 10x list" is mostly ABCL/RXRX/TXG-shaped, that's a tell the enabler layer is the durable trade and the headline sector is the wrapper.

Watch: VANQUISH Phase-3 readouts (the only thing that promotes obesity from watch-only to a live thesis); ABCL/RXRX partnership cadence as the real AI-discovery signal; whether a fresh next-gen-obesity M&A print re-rates the peptide-economy bucket enough to justify writing the perspective.